Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight(The Ohio State University Wexner Medical Center), Mark J. Smyth(Peter MacCallum Cancer Centre)
Cited by 270
Related Papers
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639